Chow WH, Dong LM, Devesa SS (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 7(5):245–257. https://doi.org/10.1038/nrurol.2010.46
Article
PubMed
PubMed Central
Google Scholar
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M et al (2017) Renal cell carcinoma. Nat Rev Dis Primers 3:17009. https://doi.org/10.1038/nrdp.2017.9
Article
PubMed
PubMed Central
Google Scholar
Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L et al (2016) Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 17(9):1317–1324
Article
Google Scholar
Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. https://doi.org/10.1093/annonc/mdr362
Article
CAS
PubMed
Google Scholar
Breau RH, Blute ML (2010) Surgery for renal cell carcinoma metastases. Curr Opin Urol 20:375–378. https://doi.org/10.1097/MOU.0b013e32833c7ada
Article
PubMed
Google Scholar
Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH et al (2009) Guideline for management of the clinical T1 renal mass. J Urol 182(4):1271–1279. https://doi.org/10.1016/j.juro.2009.07.004
Article
PubMed
Google Scholar
Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58(3):398–406. https://doi.org/10.1016/j.eururo.2010.06.032
Article
PubMed
Google Scholar
National Comprehensive Cancer Network. (2014) Kidney cancer. NCCN Clinical Practice Guideline in Oncology (NCCN GuidelinesTM) Version 1
Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875. https://doi.org/10.1056/NEJM199609193351207
Article
CAS
PubMed
Google Scholar
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540. https://doi.org/10.1200/JCO.1999.17.8.2530
Article
CAS
PubMed
Google Scholar
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318. https://doi.org/10.1200/JCO.2008.19.5511
Article
CAS
PubMed
Google Scholar
Motzer RJ, Hutson TE, Tomczak P, Dror Michaelson M, Bukowski RM, Oudard S et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590. https://doi.org/10.1200/JCO.2008.20.1293
Article
CAS
PubMed
PubMed Central
Google Scholar
Den Hengst WA, Hendriks JMH, Van Schil PEY (2011) Lung metastatic disease: surgical resection and locoregional chemotherapy. J Thorac Oncol 6:1373–1378. https://doi.org/10.5152/tcb.2012.29
Article
Google Scholar
Tannir NM (2014) Renal cell carcinoma. Oxford University Press, New York, pp 10–11
Google Scholar
Delahunt B, Algaba F, Eble J, Cheville J, Amin MB, Algani P et al. (2016) Papillary renal cell carcinoma. World Health organisation classication of tumours. Pathology and genetics of tumours of the urinary system and male genital system. 4th Edn, Lyon, IARC Press, pg 21–23
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs -part A: renal, penile, and testicular tumours. Eur Urol 70(1):93–105. https://doi.org/10.1016/j.eururo.2016.02.029
Article
PubMed
Google Scholar
Haas NB, Nathanson KL (2014) Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 21(1):81–90. https://doi.org/10.1053/j.ackd.2013.10.001
Article
PubMed
Google Scholar
Adeniran AJ, Shuch B, Humphrey PA (2015) Hereditary renal cell carcinoma syndromes: clinical, pathologic, and genetic features. Am J Surg Pathol 39(12):e1–e18. https://doi.org/10.1097/PAS.0000000000000562
Article
PubMed
Google Scholar
Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P (2005) Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 114(1):101–108. https://doi.org/10.1002/ijc.20618
Article
CAS
PubMed
Google Scholar
Pischon T, Lahmann PH, Boeing H, Tjønneland A, Halkjaer J, Overvad K et al (2006) Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 118(3):728–738. https://doi.org/10.1002/ijc.21398
Article
CAS
PubMed
Google Scholar
Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A et al (2008) Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 167(4):438–446. https://doi.org/10.1093/aje/kwm321
Article
PubMed
Google Scholar
Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P et al (2009) Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev 18(3):801–807. https://doi.org/10.1158/1055-9965.EPI-08-0601
Article
PubMed
PubMed Central
Google Scholar
Lane BR, Canter DJ, Rini BI, Uzzo RG (2015) Cancer of the kidney. In: Devit VT, Lawrence TS, Rosenberg SA (eds) DeVita, Hellman, and Rosenberg’s principles and practice of oncology, 10th edn. Wolters Kluwer Health, Philadelphia, pp 865–884
Google Scholar
Delahunt B, Eble JN (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol Off J U S Can Acad Pathol Inc 10:537–544
CAS
Google Scholar
Mejean A, Hopirtean V, Bazin JP, Larousserie F, Benoit H, Chretien Y et al (2003) Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol 170:764–767. https://doi.org/10.1097/01.ju.0000081122.57148.ec
Article
PubMed
Google Scholar
Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM (2001) Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 32:590–595. https://doi.org/10.1053/hupa.2001.24984
Article
CAS
PubMed
Google Scholar
Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M et al (2007) Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 69:230–235. https://doi.org/10.1016/j.urology.2006.09.052
Article
PubMed
Google Scholar
Allory Y, Ouazana D, Boucher E, Thiounn N, Vieillefond A (2003) Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases. Virtuous Arch Int J Pathol 442:336–442. https://doi.org/10.1007/s00428-003-0787-1
Article
Google Scholar
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C et al (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma the cancer genome atlas research network. N Engl J Med 374(2):135–145. https://doi.org/10.1056/NEJMoa1505917
Article
CAS
PubMed
Google Scholar
Petejova N, Martinek A (2016) Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 160(2):183–194. https://doi.org/10.5507/bp.2015.050
Article
PubMed
Google Scholar
Appleman LJ (2011) MET signaling pathway: a rational target for cancer therapy. J Clin Oncol 29:4837–4838. https://doi.org/10.1200/JCO.2011.37.7929
Article
CAS
PubMed
Google Scholar
Petrini I (2015) Biology of MET: a double life between normal tissue repair and tumor progression. Ann Transl Med. 3:82. https://doi.org/10.3978/j.issn.2305-5839.2015.03.58
Article
CAS
PubMed
PubMed Central
Google Scholar
Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED et al (2005) A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 174(5):1759–1763. https://doi.org/10.1097/01.ju.0000177487.64651.3adiscussion 63
Article
PubMed
Google Scholar
Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076. https://doi.org/10.1097/01.ju.0000110610.61545.ae
Article
PubMed
Google Scholar
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659. https://doi.org/10.1056/NEJMoa003013
Article
CAS
PubMed
Google Scholar
Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970. https://doi.org/10.1016/s0140-6736(01)06103-7
Article
CAS
PubMed
Google Scholar
Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM et al (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150(2 Pt 1):463–466. https://doi.org/10.1016/s0022-5347(17)35514-3
Article
CAS
PubMed
Google Scholar
Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F et al (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338:1265–1271. https://doi.org/10.1056/nejm199804303381804
Article
CAS
PubMed
Google Scholar
Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich BC, Ljungberg B et al (2019) Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol 2(2):141–149. https://doi.org/10.1016/j.euo.2018.08.028
Article
PubMed
Google Scholar
Zhao Y, Li J, Li C, Fan J, Lui L (2017) Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: a systematic review and meta-analysis. Int J Surg 41:70–77. https://doi.org/10.1016/j.ijsu.2017.03.062
Article
PubMed
Google Scholar
Ohtaki Y, Shimizu K, Aokage K, Nakao M, Yoshida J, Kamiyoshihara M et al (2017) Histology is a prognostic indicator after pulmonary metastasectomy from renal cell carcinoma. World J Surg 41(3):771–779. https://doi.org/10.1007/s00268-016-3802-9
Article
PubMed
Google Scholar
Baier B, Kern A, Kaderali L, Bis B, Koschel D, Rolle A (2015) Retrospective survival analysis of 237 consecutive patients with multiple pulmonary metastases from advanced renal cell carcinoma exclusively resected by a 1318-nm laser. Interact CardioVasc Thorac Surg 21:211–217. https://doi.org/10.1093/icvts/ivv120
Article
PubMed
Google Scholar
Murthy SC, Kim K, Rice TW, Rajeswaran J, Bukowski R, DeCamp MM et al (2005) Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 79:996–1003. https://doi.org/10.1016/j.athoracsur.2004.08.034
Article
PubMed
Google Scholar
Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 73:1082–1087. https://doi.org/10.1016/s0003-4975(01)03602-5
Article
PubMed
Google Scholar
Friedel G, Hurtgen M, Penzenstadler M, Kyriss T, Toomes H (1999) Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res 19(2C):1593–1596
CAS
PubMed
Google Scholar
Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74:1653–1657
Article
Google Scholar
Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF et al (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57:339–344
Article
CAS
Google Scholar
Hofmann HS, Neef H, Krohe K, Andreev P, Silber R-E (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48:77–81. https://doi.org/10.1016/j.eururo.2005.03.004discussion 81-2
Article
PubMed
Google Scholar
Downey RJ (1999) Surgical treatment of pulmonary metastases. Surg Oncol Clin N Am 8:341
Article
CAS
Google Scholar
Van Schil PE (2002) Surgical treatment for pulmonary metastases. Acta Clin Belg 57:333–339
Article
Google Scholar
Motzer RJ, Vogelzang NJ (1997) Chemotherapy for renal cell carcinoma. In: Raghaven D, Scher HI, Leibel SA et al (eds) Principles and practice of genitourinary oncology. Lippincott- Raven, Philadelphia, pp 885–896
Google Scholar
Oxelmark E, Hornberg JJ (2007) Finding the way in the jungle of kinase drug targets. Drug Discov Today Technol 4(3–4):e91–e95
Article
Google Scholar
Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discovery 5(10):835–844. https://doi.org/10.1038/nrd2130
Article
CAS
PubMed
Google Scholar
Motzer RJ, Hutson TE, Tomczak P, Dror Michaelson M, Bukowski RM, Rixe O et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124. https://doi.org/10.1056/NEJMoa065044
Article
CAS
PubMed
Google Scholar
Figlin R, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Négrier S et al (2008) Overall survival with sunitinib versus interferon (IFN)–alfa as first–line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 26:5024
Article
Google Scholar
Szczylik T, Demkow M, Staehler F, Rolland F, Negrier S, Hutson TE et al (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 25(18):5025
Article
Google Scholar
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281. https://doi.org/10.1056/NEJMoa066838
Article
CAS
PubMed
Google Scholar
Motzer R, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double–blind, randomized, placebo–controlled phase III trial. The Lancet 372:449–456. https://doi.org/10.1016/S0140-6736(08)61039-9
Article
CAS
Google Scholar
Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ et al (2008) Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 102:692–696. https://doi.org/10.1111/j.1464-410X.2008.07660.x
Article
PubMed
Google Scholar
Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G et al (2010) Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 28:1502–1507. https://doi.org/10.1200/JCO.2009.24.7759
Article
CAS
PubMed
PubMed Central
Google Scholar
Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA et al (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181:518–523. https://doi.org/10.1016/j.juro.2008.10.001discussion 523
Article
CAS
PubMed
Google Scholar
van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, Bex A, de Gast G, Haanen JBAG et al (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14:2431–2436. https://doi.org/10.1158/1078-0432.CCR-07-4089
Article
PubMed
Google Scholar
Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ et al (2019) Management of advanced kidney cancer: kidney cancer research network of Canada (KCRNC) consensus update 2019. Can Urol Assoc J 13(10):343–354. https://doi.org/10.5489/cuaj.6256
Article
PubMed
PubMed Central
Google Scholar
Siva S, Pham D, Gill S, Corcoran NM, Foroudi F (2012) A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int 110:E737–E743. https://doi.org/10.1111/j.1464-410X.2012.11550.x
Article
PubMed
Google Scholar
Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH et al (2017) Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int 120:623–630. https://doi.org/10.1111/bju.13811
Article
PubMed
Google Scholar
Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E et al (2017) Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35(35):3916–3923. https://doi.org/10.1200/JCO.2017.73.5324
Article
CAS
PubMed
PubMed Central
Google Scholar
Schips L, Lipsky K, Zigeuner R, Salfellner M, Winkler S, Langner C et al (2003) Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology. 62(6):1024–1028. https://doi.org/10.1016/s0090-4295(03)00763-5
Article
PubMed
Google Scholar
Woldu SL, Matulay JT, Clinton TN et al (2018) Incidence and outcomes of delayed targeted therapy after cytoreductive nephrectomy for metastatic renal-cell carcinoma: a nationwide cancer registry study. Clin Genitourin Cancer 16:e1221–e1235. https://doi.org/10.1016/j.clgc.2018.08.001
Article
PubMed
Google Scholar